Website value calculator & SEO Checker => msfaccess.org
SEO report with information and free domain appraisal for msfaccess.org. It is a domain hosted in . Its server is hosted on IP 52.212.115.228. The domain is ranked at the number 267806 as a world ranking of web pages. According to estimated data we have access to potential gains of this site are 189 dollars per month. In annual terms, the domain msfaccess.org could be earning more than 2273 dollars. If someone wanted to buy the domain a good selling price would be 22726 dollars.
These data are estimated and can not be taken as 100 % real. Only give an estimate of profits depending on the subject and the traffic generated by msfaccess.org . The estimated number of unique visitors accessing msfaccess.org is 1655. Thus the total number of people who visit this page per month would be 49641 people.
Domain Authority
SEO Score
☰ Report Resume
- SEO score
- Speed
- Page Load Time
- Current Ip of the domain: 52.212.115.228
- Charset of page: UTF-8
- Total Keywords: 2428
- Total Links: Anchor textTypeLinkSkip to main contentfollow#main-contentfollow/Media roomfollow/media-roomContactfollow/contact-usmsf.orgfollowhttps://www.msf.orgAbout usfollow/about-usAbout the Access Campaignfollow/about-usOur 2021 wishlist 🌟follow/node/492206Media roomfollow/media-roomLatest newsfollow/search?f%5B0%5D=types_of_content%3A48&f%5B1%5D=types_of_content%3A1&f%5B2%5D=types_of_content%3A3&f%5B3%5D=types_of_content%3A47&f%5B4%5D=types_of_content%3A13&f%5B5%5D=types_of_content%3A2&f%5B6%5D=types_of_content%3A4&f%5B7%5D=types_of_content%3A12Jobsfollow/vacanciesRead and share our wishesfollow/wishlist2020privacy policyfollowhttps://msfaccess.org/privacy-and-personal-data-protection-policyOur workfollow/our-workCOVID-19follow/covid-19-actionExplainer: A bold proposal at the WTO by India and South Africafollow/5-reasons-new-proposal-india-and-south-africa-could-be-gamechanger-covid-19-responseDiabetesfollow/diabetesDrug-resistant infectionsfollow/antimicrobial-resistanceHIV/AIDSfollow/hiv-aidsHepatitis Cfollow/hepatitis-cPatents and intellectual propertyfollow/patents-and-intellectual-propertyThe Patent Oppositions Databasefollowhttps://www.patentoppositions.orgSpotlight on: Access to medicines in Europefollow/access-affordable-medicines-growing-global-challenge-europe-no-exceptionSpotlight on: TRIPS, TRIPS Plusfollow/spotlight-trips-trips-plus-and-dohaResearch and developmentfollow/research-and-developmentSpotlight on: the Big Pharma double-dipfollow/how-big-pharma-making-people-pay-twice-many-medicines-they-buyTropical and neglected diseasesfollow/tropical-and-neglected-diseasesSpotlight on: Snakebitefollow/spotlight-snakebiteTuberculosisfollow/tuberculosisVaccinesfollow/vaccinesExplainer: COVID-19 vaccines - Recommendations for equitable accessfollow/covid-19-vaccines-recommendations-equitable-accessShare the Tech - Save Livesfollow/sharethetechRead and share our wishesfollow/wishlist2020privacy policyfollowhttps://msfaccess.org/privacy-and-personal-data-protection-policyGet involvedfollow/our-campaignsActive campaignsfollow/our-campaigns🦠 No Patents in a Pandemicfollow/no-patents-no-monopolies-pandemic20 years of Advocacy in Actionfollowhttps://20years.msfaccess.orgShare the Tech - Save Livesfollow/sharethetechCampaign success storiesfollow/campaign-success-stories#NoMoreTears Johnson & Johnson Can you hear us?followhttps://nomoretears.msfaccess.orgNovartis "Drop the case"follow/drop-case-campaign-picturesTrans-pacific Partnership (TPP)follow/tpp-campaign-picturesprivacy policyfollowhttps://msfaccess.org/privacy-and-personal-data-protection-policyResourcesfollow/search?f%5B0%5D=primary_topics%3A3366&f%5B1%5D=primary_topics%3A3026&f%5B2%5D=primary_topics%3A67&f%5B3%5D=primary_topics%3A27&f%5B4%5D=primary_topics%3A59&f%5B5%5D=primary_topics%3A61&f%5B6%5D=primary_topics%3A65&f%5B7%5D=primary_topics%3A66&f%5B8%5D=primary_topics%3A62&f%5B9%5D=primary_topics%3A63&f%5B10%5D=primary_topics%3A64&f%5B11%5D=primary_topics%3A28⚠️ COVID-19follow/search?f%5B0%5D=primary_topics%3A3366&keys=Eventsfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A48Feature storiesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A49Infographicsfollow/infographicsInterviewsfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A13Lettersfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A3Opinion articlesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A47Photo storiesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A8Press releasesfollow/search?f%5B0%5D=types_of_content%3A1&sort_by=field_published_atPublicationsfollow/search?f%5B0%5D=types_of_content%3A1301&f%5B1%5D=types_of_content%3A5&f%5B2%5D=types_of_content%3A4&f%5B3%5D=types_of_content%3A1511&f%5B4%5D=types_of_content%3A6&keys=Fact sheetsfollow/search?f%5B0%5D=types_of_content%3A1301&keys=Issue briefsfollow/issue-briefsReportsfollow/reportsReport seriesfollow/search?f%5B0%5D=types_of_content%3A1511&keys=&sort_by=field_published_atTechnical briefsfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A6All typesfollow/search?f%5B0%5D=types_of_content%3A1301&f%5B1%5D=types_of_content%3A5&f%5B2%5D=types_of_content%3A1&f%5B3%5D=types_of_content%3A4&f%5B4%5D=types_of_content%3A6&keys=Research articlesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A12Statementsfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A2Topic overview pagesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A821Spotlight pagesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A826Videosfollow/videosBlogfollowhttps://msfaccess.org/access-campaign-blog-discussion-space-about-fair-access-medicinesNewsletterfollowhttps://msfaccess.org/access-campaign-newslettersRead and share our wishesfollow/wishlist2020privacy policyfollowhttps://msfaccess.org/privacy-and-personal-data-protection-policyMedia roomfollow/media-roomContactfollow/contact-usmsf.orgfollowhttps://www.msf.orgAbout usfollow/about-usAbout the Access Campaignfollow/about-usOur 2021 wishlist 🌟follow/node/492206Media roomfollow/media-roomLatest newsfollow/search?f%5B0%5D=types_of_content%3A48&f%5B1%5D=types_of_content%3A1&f%5B2%5D=types_of_content%3A3&f%5B3%5D=types_of_content%3A47&f%5B4%5D=types_of_content%3A13&f%5B5%5D=types_of_content%3A2&f%5B6%5D=types_of_content%3A4&f%5B7%5D=types_of_content%3A12Jobsfollow/vacanciesRead and share our wishesfollow/wishlist2020privacy policyfollowhttps://msfaccess.org/privacy-and-personal-data-protection-policyOur workfollow/our-workCOVID-19follow/covid-19-actionExplainer: A bold proposal at the WTO by India and South Africafollow/5-reasons-new-proposal-india-and-south-africa-could-be-gamechanger-covid-19-responseDiabetesfollow/diabetesDrug-resistant infectionsfollow/antimicrobial-resistanceHIV/AIDSfollow/hiv-aidsHepatitis Cfollow/hepatitis-cPatents and intellectual propertyfollow/patents-and-intellectual-propertyThe Patent Oppositions Databasefollowhttps://www.patentoppositions.orgSpotlight on: Access to medicines in Europefollow/access-affordable-medicines-growing-global-challenge-europe-no-exceptionSpotlight on: TRIPS, TRIPS Plusfollow/spotlight-trips-trips-plus-and-dohaResearch and developmentfollow/research-and-developmentSpotlight on: the Big Pharma double-dipfollow/how-big-pharma-making-people-pay-twice-many-medicines-they-buyTropical and neglected diseasesfollow/tropical-and-neglected-diseasesSpotlight on: Snakebitefollow/spotlight-snakebiteTuberculosisfollow/tuberculosisVaccinesfollow/vaccinesExplainer: COVID-19 vaccines - Recommendations for equitable accessfollow/covid-19-vaccines-recommendations-equitable-accessShare the Tech - Save Livesfollow/sharethetechRead and share our wishesfollow/wishlist2020privacy policyfollowhttps://msfaccess.org/privacy-and-personal-data-protection-policyGet involvedfollow/our-campaignsActive campaignsfollow/our-campaigns🦠 No Patents in a Pandemicfollow/no-patents-no-monopolies-pandemic20 years of Advocacy in Actionfollowhttps://20years.msfaccess.orgShare the Tech - Save Livesfollow/sharethetechCampaign success storiesfollow/campaign-success-stories#NoMoreTears Johnson & Johnson Can you hear us?followhttps://nomoretears.msfaccess.orgNovartis "Drop the case"follow/drop-case-campaign-picturesTrans-pacific Partnership (TPP)follow/tpp-campaign-picturesprivacy policyfollowhttps://msfaccess.org/privacy-and-personal-data-protection-policyResourcesfollow/search?f%5B0%5D=primary_topics%3A3366&f%5B1%5D=primary_topics%3A3026&f%5B2%5D=primary_topics%3A67&f%5B3%5D=primary_topics%3A27&f%5B4%5D=primary_topics%3A59&f%5B5%5D=primary_topics%3A61&f%5B6%5D=primary_topics%3A65&f%5B7%5D=primary_topics%3A66&f%5B8%5D=primary_topics%3A62&f%5B9%5D=primary_topics%3A63&f%5B10%5D=primary_topics%3A64&f%5B11%5D=primary_topics%3A28⚠️ COVID-19follow/search?f%5B0%5D=primary_topics%3A3366&keys=Eventsfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A48Feature storiesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A49Infographicsfollow/infographicsInterviewsfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A13Lettersfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A3Opinion articlesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A47Photo storiesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A8Press releasesfollow/search?f%5B0%5D=types_of_content%3A1&sort_by=field_published_atPublicationsfollow/search?f%5B0%5D=types_of_content%3A1301&f%5B1%5D=types_of_content%3A5&f%5B2%5D=types_of_content%3A4&f%5B3%5D=types_of_content%3A1511&f%5B4%5D=types_of_content%3A6&keys=Fact sheetsfollow/search?f%5B0%5D=types_of_content%3A1301&keys=Issue briefsfollow/issue-briefsReportsfollow/reportsReport seriesfollow/search?f%5B0%5D=types_of_content%3A1511&keys=&sort_by=field_published_atTechnical briefsfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A6All typesfollow/search?f%5B0%5D=types_of_content%3A1301&f%5B1%5D=types_of_content%3A5&f%5B2%5D=types_of_content%3A1&f%5B3%5D=types_of_content%3A4&f%5B4%5D=types_of_content%3A6&keys=Research articlesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A12Statementsfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A2Topic overview pagesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A821Spotlight pagesfollow/search?keys=&sort_by=field_published_at&f%5B0%5D=types_of_content%3A826Videosfollow/videosBlogfollowhttps://msfaccess.org/access-campaign-blog-discussion-space-about-fair-access-medicinesNewsletterfollowhttps://msfaccess.org/access-campaign-newslettersRead and share our wishesfollow/wishlist2020privacy policyfollowhttps://msfaccess.org/privacy-and-personal-data-protection-policyTake action! Get involvedfollow/no-patents-no-monopolies-pandemicShare the Techfollow/sharethetechNo Patents, No Monopolies in a Pandemicfollow/no-patents-no-monopolies-pandemicAs Moderna releases astronomical Q3 sales figures, MSF tells the corporation it’s high time to share the technology with WHO mRNA vaccine tech transfer Hub in South Africafollow/moderna-releases-astronomical-q3-sales-figures-msf-tells-corporation-its-high-time-share-technologyCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=Read morefollow/moderna-releases-astronomical-q3-sales-figures-msf-tells-corporation-its-high-time-share-technologyfollow#main-contentMSF response to first regulatory approval of first oral antiviral treatment for COVID-19, molnupiravirfollow/msf-response-first-regulatory-approval-first-oral-antiviral-treatment-covid-19-molnupiravirLessons learned and recommendations to ensure access to vaccines, medicines and diagnostics in the COVID-19 pandemic response and beyondfollow/lessons-learned-and-recommendations-ensure-access-vaccines-medicines-and-diagnostics-covid-19MSF responds to BioNTech’s announcement that it will establish production facilities in African countriesfollow/msf-responds-biontechs-announcement-it-will-establish-production-facilities-african-countriesLicense between Merck and Medicines Patent Pool for global production of promising new COVID-19 drug molnupiravir disappoints in its access limitationsfollow/license-between-merck-and-medicines-patent-pool-global-production-promising-new-covid-19-drugToxicon: X: Access to antivenoms in the developing world: A multidisciplinary analysisfollow/toxicon-x-access-antivenoms-developing-world-multidisciplinary-analysisBMJ Global Health: Snakebites and COVID-19: two crises, one R&D opportunityfollow/bmj-global-health-snakebites-and-covid-19-two-crises-one-rd-opportunityLetter to Cepheid to reinstate launch of GeneXpert Omni TB testing systemfollow/letter-cepheid-reinstate-launch-genexpert-omni-tb-testing-systemMSF responds to another misleading attempt by EU to undermine TRIPS Waiverfollow/msf-responds-another-misleading-attempt-eu-undermine-trips-waiverMSF warns of deadly TB testing gap following release of WHO Global TB Report 2021follow/msf-warns-deadly-tb-testing-gap-following-release-who-global-tb-report-2021As time runs out to break ‘TRIPS Waiver’ stalemate, protesters at US and EU embassies in South Africa warn “The whole world is watching you.”follow/time-runs-out-break-trips-waiver-stalemate-protesters-us-and-eu-embassies-south-africa-warn-wholeSouth Africa: CSO letters to the embassies of countries opposing the TRIPS waiverfollow/south-africa-cso-letters-embassies-countries-opposing-trips-waiverMSF responds to news of Merck filing for US FDA Emergency Use Authorization for the potential oral COVID-19 treatment molnupiravirfollow/msf-responds-news-merck-filing-us-fda-emergency-use-authorization-potential-oral-covid-19-treatment@MSF_accessfollowhttps://twitter.com/MSF_access4 days agofollowhttps://twitter.com/MSF_access/status/14565794379825356824 reasons why pharma corporations must share their full #COVID19 vaccine technology with producers on the African continent, now.#ShareTheTech #VaccineEquity #ChangeNotCharity @moderna_tx @pfizer @BioNTech_Group msfaccess.org/4-reasons-why-…followhttps://twitter.com/MSF_access/status/1456579437982535682@MSF_accessfollowhttps://twitter.com/MSF_access4 days 1 hour agofollowhttps://twitter.com/MSF_access/status/1456561223382839296A thread🧵 with 4 reasons why @moderna_tx, @pfizer & @BioNTech_Group must urgently share their full mRNA vaccine technology with producers on the African continent:#ShareTheTech #VaccineEquity msfaccess.org/4-reasons-why-…followhttps://twitter.com/MSF_access/status/1456561223382839296@MSF_accessfollowhttps://twitter.com/MSF_access4 days 6 hours agofollowhttps://twitter.com/MSF_access/status/1456486560707268610We have the tools to protect people in low- & middle-income countries from #COVID19.The only reason mRNA vaccines aren’t being produced more widely is because @moderna_tx, @pfizer & @BioNTech_Group aren’t allowing it.#VaccineEquity #ShareTheTech msfaccess.org/4-reasons-why-…followhttps://twitter.com/MSF_access/status/1456486560707268610@MSF_accessfollowhttps://twitter.com/MSF_access4 days 9 hours agofollowhttps://twitter.com/MSF_access/status/1456441280070922264💬 “If @moderna_tx were to share its tech with the @WHO mRNA Hub, the company could help increase the global production of COVID-19 vaccines now.” We’re calling on pharma corporations to #ShareTheTech to save lives. ⬇️ #VaccineEquityfollowhttps://twitter.com/MSF_access/status/1456441280070922264@MSF_accessfollowhttps://twitter.com/MSF_access4 days 12 hours agofollowhttps://twitter.com/MSF_access/status/1456396118200393735Over 5 million people have died from COVID-19. We now have a lifesaving mRNA vaccine available. Doing everything possible to end the pandemic includes sharing the vaccine tech with the world. @moderna_tx, stop choosing who gets to live. #ShareTheTechfollowhttps://twitter.com/MSF_access/status/1456396118200393735follow/sharethetechHow you can supportfollow/sharethetechfollow/no-patents-no-monopolies-pandemicHow you can supportfollow/no-patents-no-monopolies-pandemicFeature storyfollow/people-facing-pandemicCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=The People Facing the Pandemicfollow/people-facing-pandemicExplainerfollow/4-reasons-why-pfizer-biontech-and-moderna-must-share-covid-19-mrna-vaccine-technology-nowCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=4 reasons why Pfizer, BioNTech and Moderna must share COVID-19 mRNA vaccine technology NOW!follow/4-reasons-why-pfizer-biontech-and-moderna-must-share-covid-19-mrna-vaccine-technology-nowCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=3 reasons why the EU’s TRIPS Waiver counter-proposal is an insufficient solution in a pandemicfollow/3-reasons-why-eus-trips-waiver-counter-proposal-insufficient-solution-pandemicSpotlightfollow/covid-19-vaccines-recommendations-equitable-accessCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=COVID-19 vaccines: Recommendations for equitable accessfollow/covid-19-vaccines-recommendations-equitable-accessCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=5 reasons a new proposal by India and South Africa could be a gamechanger in the COVID-19 responsefollow/5-reasons-new-proposal-india-and-south-africa-could-be-gamechanger-covid-19-responsePress releasefollow/moderna-releases-astronomical-q3-sales-figures-msf-tells-corporation-its-high-time-share-technologyCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=As Moderna releases astronomical Q3 sales figures, MSF tells the corporation it’s high time to share the technology with WHO mRNA vaccine tech transfer Hub in South Africafollow/moderna-releases-astronomical-q3-sales-figures-msf-tells-corporation-its-high-time-share-technologyfollow/lessons-learned-and-recommendations-ensure-access-vaccines-medicines-and-diagnostics-covid-19COVID-19follow/search?f[0]=primary_topics%3A3366&keys=Lessons learned and recommendations to ensure access to vaccines, medicines and diagnostics in the COVID-19 pandemic response and beyondfollow/lessons-learned-and-recommendations-ensure-access-vaccines-medicines-and-diagnostics-covid-19Press releasefollow/msf-responds-biontechs-announcement-it-will-establish-production-facilities-african-countriesCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=MSF responds to BioNTech’s announcement that it will establish production facilities in African countriesfollow/msf-responds-biontechs-announcement-it-will-establish-production-facilities-african-countriesLoad Morefollow?tid=All&page=1Tuberculosisfollow/tuberculosisStep Up for TB: TB policies in 37 countries, 4th Ed.follow/step-tb-tb-policies-37-countries-4th-edTuberculosisfollow/tuberculosisDR-TB and TB-Prevention Drugs Under the Microscope, 7th Editionfollow/dr-tb-and-tb-prevention-drugs-under-microscope-7th-editionDiabetesfollow/diabetesA century of neglect: challenges of access to insulin for diabetes carefollow/century-neglect-challenges-access-insulin-diabetes-careVaccinesfollow/vaccinesA Fair Shot for Vaccine Affordabilityfollow/fair-shot-vaccine-affordabilityfollowhttps://vimeo.com/530716152100 years of insulinfollow/100-years-insulinRead morefollow/100-years-insulinfollowhttps://vimeo.com/520908247/8e17ef256bMSF International President appeals to governments blocking landmark COVID-19 proposalfollow/msf-international-president-appeals-governments-blocking-landmark-covid-19-proposalRead morefollow/msf-international-president-appeals-governments-blocking-landmark-covid-19-proposalfollowhttps://vimeo.com/420634173COVID-19: No patents or profiteering in a pandemicfollow/covid-19-no-patents-or-profiteering-pandemicRead morefollow/covid-19-no-patents-or-profiteering-pandemicfollowhttps://vimeo.com/404534453No monopolies - Access to COVID-19 treatmentfollow/no-monopolies-access-covid-19-treatmentRead morefollow/no-monopolies-access-covid-19-treatmentfollowhttps://vimeo.com/328402119/749858619eLives Over Profit: a Patient, a Doctor and a Lawyer Take Actionfollow/lives-over-profit-patient-doctor-and-lawyer-take-actionRead morefollow/lives-over-profit-patient-doctor-and-lawyer-take-actionfollowhttps://vimeo.com/220461300A Snapshot of the Access Campaignfollow/snapshot-access-campaignRead morefollow/snapshot-access-campaign20 Years of Advocacy in Action - JOIN US!followhttps://20years.msfaccess.orgCOVID-19follow/covid-19-actionDrug-resistant infectionsfollow/drug-resistant-infectionsDiabetesfollow/diabetesHepatitis Cfollow/hepatitis-cHIV/AIDSfollow/hiv-aidsTropical & neglected diseasesfollow/tropical-and-neglected-diseasesTuberculosisfollow/tuberculosisVaccinesfollow/vaccinesPatents & intellectual propertyfollow/patents-and-intellectual-propertyResearch & developmentfollow/research-and-developmentFeature storyfollow/people-facing-pandemicCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=The People Facing the Pandemicfollow/people-facing-pandemicSpotlightfollow/covid-19-vaccines-recommendations-equitable-accessCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=COVID-19 vaccines: Recommendations for equitable accessfollow/covid-19-vaccines-recommendations-equitable-accessCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=5 reasons a new proposal by India and South Africa could be a gamechanger in the COVID-19 responsefollow/5-reasons-new-proposal-india-and-south-africa-could-be-gamechanger-covid-19-responseIntellectual property and tradefollow/patents-and-intellectual-propertyPatent Oppositions Databasefollowhttps://www.patentoppositions.org/Spotlightfollow/how-big-pharma-making-people-pay-twice-many-medicines-they-buyResearch and developmentfollow/research-and-developmentHow Big Pharma is making people pay twice for many of the medicines they buyfollow/how-big-pharma-making-people-pay-twice-many-medicines-they-buyCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=3 reasons why we need a Waiver on monopolies of ALL COVID-19 medical toolsfollow/3-reasons-why-we-need-waiver-monopolies-all-covid-19-medical-toolsCOVID-19follow/search?f[0]=primary_topics%3A3366&keys=MSF’s recommendations to control the ongoing COVID-19 pandemicfollow/msfs-recommendations-control-ongoing-covid-19-pandemicBlogfollowhttps://msf-access.medium.com/jak-inhibitors-promising-treatment-for-people-with-severe-covid-19-illness-2b14e812a434COVID-19follow/search?f[0]=primary_topics%3A3366&keys=JAK inhibitors: promising treatment for people with severe COVID-19 illness. But will they be affordable for all?followhttps://msf-access.medium.com/jak-inhibitors-promising-treatment-for-people-with-severe-covid-19-illness-2b14e812a434Load Morefollow?tid=All&page=1@DimitriEynikelfollowhttps://twitter.com/DimitriEynikelfollowhttps://twitter.com/DimitriEynikel/status/1457685733922201601Pharmaceutical companies are blocking #covid19 #vaccine donations by EU member states to other countries, this is what the German State Secretary of Health wrote to the @EU_Commission. 👇The companies refuse to give their consent to the donations out of commercial interests. 1/ twitter.com/ThiruGeneva/st…followhttps://twitter.com/DimitriEynikel/status/145768573392220160100:25 - 08 Nov 2021followhttps://twitter.com/DimitriEynikel/status/1457685733922201601followhttps://twitter.com/intent/tweet?in_reply_to=1457685733922201601followhttps://twitter.com/intent/retweet?tweet_id=1457685733922201601followhttps://twitter.com/intent/like?tweet_id=1457685733922201601@MSF_accessfollowhttps://twitter.com/MSF_accessfollowhttps://twitter.com/MSF_access/status/14565794379825356824 reasons why pharma corporations must share their full #COVID19 vaccine technology with producers on the African continent, now.#ShareTheTech #VaccineEquity #ChangeNotCharity @moderna_tx @pfizer @BioNTech_Group msfaccess.org/4-reasons-why-…followhttps://twitter.com/MSF_access/status/145657943798253568201:09 - 05 Nov 2021followhttps://twitter.com/MSF_access/status/1456579437982535682followhttps://twitter.com/intent/tweet?in_reply_to=1456579437982535682followhttps://twitter.com/intent/retweet?tweet_id=1456579437982535682followhttps://twitter.com/intent/like?tweet_id=1456579437982535682@MSF_accessfollowhttps://twitter.com/MSF_accessfollowhttps://twitter.com/MSF_access/status/1456561223382839296A thread🧵 with 4 reasons why @moderna_tx, @pfizer & @BioNTech_Group must urgently share their full mRNA vaccine technology with producers on the African continent:#ShareTheTech #VaccineEquity msfaccess.org/4-reasons-why-…followhttps://twitter.com/MSF_access/status/145656122338283929623:57 - 04 Nov 2021followhttps://twitter.com/MSF_access/status/1456561223382839296followhttps://twitter.com/intent/tweet?in_reply_to=1456561223382839296followhttps://twitter.com/intent/retweet?tweet_id=1456561223382839296followhttps://twitter.com/intent/like?tweet_id=1456561223382839296@MSF_accessfollowhttps://twitter.com/MSF_accessfollowhttps://twitter.com/MSF_access/status/1456486560707268610We have the tools to protect people in low- & middle-income countries from #COVID19.The only reason mRNA vaccines aren’t being produced more widely is because @moderna_tx, @pfizer & @BioNTech_Group aren’t allowing it.#VaccineEquity #ShareTheTech msfaccess.org/4-reasons-why-…followhttps://twitter.com/MSF_access/status/145648656070726861019:00 - 04 Nov 2021followhttps://twitter.com/MSF_access/status/1456486560707268610followhttps://twitter.com/intent/tweet?in_reply_to=1456486560707268610followhttps://twitter.com/intent/retweet?tweet_id=1456486560707268610followhttps://twitter.com/intent/like?tweet_id=1456486560707268610@MSF_accessfollowhttps://twitter.com/MSF_accessfollowhttps://twitter.com/MSF_access/status/1456441280070922264💬 “If @moderna_tx were to share its tech with the @WHO mRNA Hub, the company could help increase the global production of COVID-19 vaccines now.” We’re calling on pharma corporations to #ShareTheTech to save lives. ⬇️ #VaccineEquityfollowhttps://twitter.com/MSF_access/status/145644128007092226416:00 - 04 Nov 2021followhttps://twitter.com/MSF_access/status/1456441280070922264followhttps://twitter.com/intent/tweet?in_reply_to=1456441280070922264followhttps://twitter.com/intent/retweet?tweet_id=1456441280070922264followhttps://twitter.com/intent/like?tweet_id=1456441280070922264@MSF_accessfollowhttps://twitter.com/MSF_accessfollowhttps://twitter.com/MSF_access/status/1456396118200393735Over 5 million people have died from COVID-19. We now have a lifesaving mRNA vaccine available. Doing everything possible to end the pandemic includes sharing the vaccine tech with the world. @moderna_tx, stop choosing who gets to live. #ShareTheTechfollowhttps://twitter.com/MSF_access/status/145639611820039373513:01 - 04 Nov 2021followhttps://twitter.com/MSF_access/status/1456396118200393735followhttps://twitter.com/intent/tweet?in_reply_to=1456396118200393735followhttps://twitter.com/intent/retweet?tweet_id=1456396118200393735followhttps://twitter.com/intent/like?tweet_id=1456396118200393735@MSF_accessfollowhttps://twitter.com/MSF_accessfollowhttps://twitter.com/MSF_access/status/1456365918871764998Hey @moderna_tx, as you celebrate your profits today, it’s time to take responsibility.Thanks to public funding, you created a modern-day miracle to fight COVID-19.The recipe to make this vaccine is owed to the world. Put people over profits in a pandemic. #ShareTheTechfollowhttps://twitter.com/MSF_access/status/145636591887176499811:01 - 04 Nov 2021followhttps://twitter.com/MSF_access/status/1456365918871764998followhttps://twitter.com/intent/tweet?in_reply_to=1456365918871764998followhttps://twitter.com/intent/retweet?tweet_id=1456365918871764998followhttps://twitter.com/intent/like?tweet_id=1456365918871764998@MSF_accessfollowhttps://twitter.com/MSF_accessfollowhttps://twitter.com/MSF_access/status/1456335828830019586Hey @moderna_tx,You received public funding to develop the COVID-19 vaccine.Share the tech - so manufacturers around the world can produce vaccines and get people protected ASAP.Help end the pandemic.The world is waiting.#ShareTheTech #VaccineEquity #FreeTheVaccinefollowhttps://twitter.com/MSF_access/status/145633582883001958609:01 - 04 Nov 2021followhttps://twitter.com/MSF_access/status/1456335828830019586followhttps://twitter.com/intent/tweet?in_reply_to=1456335828830019586followhttps://twitter.com/intent/retweet?tweet_id=1456335828830019586followhttps://twitter.com/intent/like?tweet_id=1456335828830019586Load Morefollow?page=1privacy policyfollowhttps://msfaccess.org/privacy-and-personal-data-protection-policyLives Over Profit: a Patient, a Doctor and a Lawyer Take Actionfollow/lives-over-profit-patient-doctor-and-lawyer-take-actionRead morefollow/lives-over-profit-patient-doctor-and-lawyer-take-actionfollowhttps://vimeo.com/328402119/749858619eAbout the Access Campaignfollow/about-us1999-2019: 20 Years of Advocacy in Actionfollowhttps://20years.msfaccess.orgContact usfollow/contact-usGet involvedfollow/our-campaignsOur workfollow/our-workResourcesfollow/search?f%5B0%5D=primary_topics%3A67&f%5B1%5D=primary_topics%3A64&f%5B2%5D=primary_topics%3A63&f%5B3%5D=primary_topics%3A28&f%5B4%5D=primary_topics%3A62&f%5B5%5D=primary_topics%3A27&f%5B6%5D=primary_topics%3A59&f%5B7%5D=primary_topics%3A66&f%5B8%5D=primary_topics%3A65&f%5B9%5D=primary_topics%3A61Searchfollow/searchSign up for our newsletterfollow/newsletterPrivacy & data protection informationfollow/privacy-and-personal-data-protection-policyfollowhttps://www.twitter.com/msf_accessTwitterfollowhttps://www.twitter.com/msf_accessfollowhttps://www.vimeo.com/msfaccessVimeofollowhttps://www.vimeo.com/msfaccessfollowhttps://www.facebook.com/MSFaccess/Facebookfollowhttps://www.facebook.com/MSFaccess/
- Social signals
- Title: 48 characters.
- Description: 80 characters.
- Domain Authority
- Monthly pages viewed: 49641
- Estimated worth: 22726 dollars
We have developed a useful service for retrieve WhoIs information. "Whois" is a term that begins from the early days of the Internet, based on Unix operating system and university networks. On the Unix console, the command "whois" tries to determine the identity of the domain's registrant.
It is a means for Internet users to query various types of information such as IP addresses, user data and also domain data.
✦ SEO Report
Title / Meta tags
MSF Access Campaign | Médecins Sans Frontières
What good is a breakthrough medicine if the people who need it cannot afford it?
Image Analysis
A right example for an HTML image tag:
<img src="prettyimage.jpg" alt="image description" title="image tooltip"/>
For SEO performance, you must write an alternative text. The alternative text must describe the image's content. Also, the alt tag is used for blind people. Their browsers tell them all about the description of the image.
Heading
Content Analysis
Code Analysis
We have not found hyphens (-) or underscores (_) in your URL. Google and expert domainers do not recommend buying domains with hyphens or underscores.
When a visitor came to your website you can not fail. The user wants your page to load in a second. You know that it is difficult sometimes to display content in the first second but if the user has to wait too much time you can lose that user. If your page is too slow, you will lose a lot of web traffic. Your project URL load time is ms, it is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.msfaccess.org is as follows:
A huge portion of visitors to your website are usually in rush and nobody is fond of waiting too much before your website loads its content. If your website is slow, you will lose a lot of visitors. Your homepage load time is ms is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.msfaccess.org is as follows:
Speed:
Page Load Time: ms
default-domain path-frontpage page-node-type-section-page msf_theme, visually-hidden focusable skip-link, dialog-off-canvas-main-canvas, header header__main-menu, header__container container clearfix, header__container--left, header__logo, header-navigation-container, header__utility, header__secondary block block-domain-menu-access block-domain-access-menu-blocksecondary-menu, menu-secondary-menu, menu-item, menu-item menu-item--collapsed, header__nav block block-domain-menu-access block-domain-access-menu-blockmain, menu menu--simple-mega-menu, menu-item menu-item--expanded, icon-arrow-down, megamenu-close-button, icon-arrow-left, mega-menu-wrapper, mega-menu-background, simple-mega-menu mega-menu-item simple-mega-menu-type-main-navigation- view-mode-default, left-column, field field-links-menu field--type-entity-reference field--label-hidden field__item, menu-drop-down-about-us, right-column, field field-image field--type-entity-reference field--label-hidden field__item, media media-image view-mode-image, field field-teaser field--type-text-long field--label-hidden field__item, text-background bg-red-text-white text-align-center text-star-headline, mega-menu-wishlist-link, field field-mailchimp-form field--type-block-field field--label-hidden field__item, mailchimp-signup-subscribe-form container__newsletter, left-column newsletter__text, newsletter__subtext, newsletter__description, right-column newsletter__form, mailchimp-newsletter-mergefields, js-form-item form-item js-form-type-email form-item-mergevars-email js-form-item-mergevars-email, js-form-required form-required, form-email required, form-actions js-form-wrapper form-wrapper, button js-form-submit form-submit, js-form-item form-item js-form-type-checkbox form-item-terms js-form-item-terms, form-checkbox required, option js-form-required form-required, description, menu-drop-down-our-work, menu-drop-down-our-campaigns, field field-title field--type-string field--label-hidden field__item, menu-drop-down-resources, header__campaign-container, header__container--right, take-action-block , block block-header-cta block-block-content block-block-contente74542de-b2db-4518-b603-1f95924bdd2f, block-header-cta__title, block-header-cta__link, block-header-cta__link-sub-text, field field-sub-text field--type-string field--label-hidden field__item, block block-block-content block-block-content77569825-4181-4dea-9c02-ae8dfb1f671f, field field-campaigns field--type-entity-reference field--label-hidden field__items, field__item, node node--type-campaign node--promoted node--sticky node--view-mode-take-action-get-invloved-menu-, node__content, title, views-exposed-form bef-exposed-form block block-views block-views-exposed-filter-blocksolr-search-content-page-1, js-form-item form-item js-form-type-search-api-autocomplete form-item-keys js-form-item-keys, form-autocomplete form-text, js-form-item form-item js-form-type-select form-item-sort-by js-form-item-sort-by, form-select, hamburger-container, hamburger-container-campaign campaign, layout-content, hidden, block block-system block-system-main-block, node node--type-section-page node--promoted node--view-mode-full node__section_page--full, field field-paragraphs field--type-entity-reference-revisions field--label-hidden field__items, paragraph hero-content paragraph--type--hero-content paragraph--view-mode--default, field field-content field--type-entity-reference field--label-hidden field__item, hero node node--type-story node--promoted node--view-mode-hero-content node__story--hero_content, bg-responsive-image hero__content bg__content bg-pos--center , image--invisible, container, hero__left, hero__meta hero__meta-top tags tags--primary tags--white, type-and-date, tags field-type-of-content, tags__item, field field-published-at field--type-datetime field--label-hidden field__item, hero__headline, hero__meta hero__meta-bottom line-left, hero__teaser, tags tags--white, tags-topics, tags-topics tags__item, hero__read-more button button--primary, sharethis-wrapper, st_facebook_custom, st_twitter_custom, st_linkedin_custom, show-more, sharethis-wrapper--extra, st_email_custom, st_sharethis_custom, st_pinterest_custom, fa fa-plus, fa fa-minus, hero__copyright, hero__scroll-down scroll-trigger icon-arrow, latest-content-wrapper, latest-content-outer container, paragraph__title, field field-latest-content field--type-entity-reference field--label-hidden field__items, views-element-container, latest-content-slider js-view-dom-id-38e6eeceb015ff3b84fcfffe6ba605662971d77f06f95c7a292e591872fca6c4, views-row, node latest-content__item node--type-story node--view-mode-latest-content, latest-content__wrapper, hero__meta hero__meta-top tags tags--primary tags--red, latest-content__link, latest-content__item-title, node latest-content__item node--type-resource node--view-mode-latest-content, paragraph latest-tweets paragraph--type--latest-tweets paragraph--view-mode--default, js-view-dom-id-8f75f4a7c8e7b7b6f35e39f789c3cc5e26b056567fefd8e576cd43116c8c0c8f, node node--type-social-stream node--promoted node--view-mode-teaser social-slider, social-slider__content, social-slider__wrapper, social-slider__icon fa fa-twitter, social-slider__user-name, social-slider__date, social-slider__title, paragraph text-columns paragraph--type--text-columns paragraph--view-mode--default clearfix, field text-columns-text field--type-text-long field--label-hidden text-columns__grid text-columns--2-columns, text-columns__item, embedded-entity embedded-entity--medium js-zoom embedded-image, media media-image view-mode-medium-image, media-inner, text-highlighted bg-black-text-white, arrow-icon-style, embedded-entity embedded-entity--big js-zoom embedded-image, media media-image view-mode-big-image, paragraph container paragraph--type--featured-content paragraph--view-mode--default, js-view-dom-id-9081c3132d459537aa98665af9b9e0a38943c42673d6107700f10ddcc5518453, views-exposed-form bef-exposed-form, js-form-item form-item js-form-type-select form-item-tid js-form-item-tid, js-hide button js-form-submit form-submit, views-infinite-scroll-content-wrapper clearfix, node node--type-story node--promoted node--sticky node--view-mode-featured-content, media-wrapper, field field-hero-image field--type-entity-reference field--label-hidden field__item, field name field--type-string field--label-hidden field__item, hero__meta hero__meta-top tags tags--primary tags--black, tags tags--black, reading-time, node node--type-story node--promoted node--sticky node--view-mode-featured-content display-as-overlay, node__content-wrapper, node node--type-story node--promoted node--view-mode-featured-content, node node--type-resource node--promoted node--view-mode-featured-content, field field-edition-image field--type-entity-reference field--label-hidden field__item, media media-image view-mode-default, image__wrapper, js-pager__items pager, pager__item, button button--primary button__load-more, pager__arrow, paragraph container paragraph--type--featured-content-manual paragraph--view-mode--default, field field-featured-content-items field--type-entity-reference field--label-hidden field__items, field__item featured-content-item, node node--type-resource node--view-mode-featured-content display-as-overlay, node node--type-resource node--promoted node--view-mode-featured-content display-as-overlay, field field-headline string field--label-hidden, paragraph featured-video-single-gallery paragraph--type--featured-video-single-gallery paragraph--view-mode--default, field field-video field--type-entity-reference field--label-hidden field--id-, field__items video_carousel, field-item video_item, node node--type-story node--promoted node--view-mode-featured-video-single-gallery- video video__single, node__video, field field-hero-video field--type-entity-reference field--label-hidden field__item, media media-video view-mode-big-video-thumbnail, video__title, video__read-more, field__items video_carousel_nav, video_image, video_title, paragraph quotes-facts-widget paragraph--type--quotes-facts-widget paragraph--view-mode--default, field field-quotes-facts, field-quotes-facts__quotes, field body field--type-text-with-summary field--label-hidden field__item, paragraph cta-section paragraph--type--cta-section paragraph--view-mode--default, cta_wrapper, container container__cta, field field-cta-section-block field--type-entity-reference field--label-hidden field__item, field field-link field--type-link field--label-hidden field__item, cta-section-block__link, paragraph featured-topics paragraph--type--featured-topics paragraph--view-mode--default featured-topics container, field field-topics-collection field--type-link field--label-hidden field__items, featured-topics__link, js-view-dom-id-5bc4ff9ab4b968f02be0edda38c81a521755ab055ef73e352076954f55696820, node node--type-external-content node--promoted node--sticky node--view-mode-featured-content display-as-overlay, node node--type-story node--promoted node--view-mode-featured-content display-as-overlay, node node--type-external-content node--promoted node--view-mode-featured-content, paragraph container paragraph--type--social-stream-wall paragraph--view-mode--default, row, social-stream clearfix js-view-dom-id-89ef4e42d5f37711d3bde83f42ef8f97fd3fccf90536d8d729ab311fe4ba4ce6, social-stream__sizer, social-stream__item, node social-stream__node node--type-social-stream node--promoted node--view-mode-default social-stream--image-empty, social-stream__icon fa fa-twitter, social-stream__meta, field field-display-name field--type-string field--label-hidden field__item, social-stream__title, intent-actions, action intent-comment, action intent-retweet, action intent-like, node social-stream__node node--type-social-stream node--promoted node--view-mode-default, field field-post-image field--type-image field--label-hidden field__item, paragraph newsletter-signup paragraph--type--newsletter-signup paragraph--view-mode--default, newsletter bg--parallax bg-responsive-image, field field-block-reference field--type-block-field field--label-hidden field__item, paragraph featured-video-full-width- paragraph--type--featured-video-full-width- paragraph--view-mode--default, field field-video field--type-entity-reference field--label-hidden field__items, node node--type-story node--promoted node--view-mode-featured-video-full-width- video video__full-width, footer, container clearfix, footer__block, footer__nav block block-domain-menu-access block-domain-access-menu-blockfooter, block-title, menu-footer, block block-block-content block-block-contenta2e29103-913d-4913-97f8-e3c91067027d, footer__updates, footer__contact, block block-block-content block-block-content190ca131-783e-431d-adb0-f14514e69395, block-social-media-links block block-social-media-links-block, social-media-links--platforms platforms vertical, social-media-link-icon--twitter, fa fa-twitter fa-2x, social-media-link--twitter, social-media-link-icon--vimeo, fa fa-vimeo-square fa-2x, social-media-link--vimeo, social-media-link-icon--facebook, fa fa-facebook fa-2x, social-media-link--facebook, footer__statement, block block-block-content block-block-content3da3c2fb-b95e-4c33-9880-a172e4670b8c, field field-statement-image field--type-entity-reference field--label-hidden field__item,
How much money does msfaccess.org earn?
The domain msfaccess.org has a revenue of $173.7435 monthly. We have calculated this earning based on the daily traffic of this domain.
Has msfaccess.org Google Analytics code?
The domain msfaccess.org has not the Google Analytics code inside its HTML.
Has msfaccess.org Google Adsense code?
The domain msfaccess.org has not the Google Adsense code inside its HTML.
What IP msfaccess.org has?
The domain msfaccess.org has IP 52.212.115.228.
Which charset msfaccess.org has?
An IP address is a string of numbers used to make devices accessible for communication.
The domain msfaccess.org has the charset UTF-8.
How many internal links msfaccess.org has?
To display an HTML page correctly, a web browser must know which character set to use.
The charset change for every language set of characters like English, Chinese or Russian.
The domain msfaccess.org has 0 links.
How many words msfaccess.org has?
The links are an important part of the web.
The links help us to navigate between pages.
The domain msfaccess.org has 2428 words.
The number of words is a crucial metric of the website.
The websites need a large quantity of text to explain the content of the site
Last visited